278 related articles for article (PubMed ID: 18329793)
21. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
Secchiero P; Melloni E; Corallini F; Beltrami AP; Alviano F; Milani D; D'Aurizio F; di Iasio MG; Cesselli D; Bagnara GP; Zauli G
Stem Cells; 2008 Nov; 26(11):2955-63. PubMed ID: 18772312
[TBL] [Abstract][Full Text] [Related]
22. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.
Sun B; Moibi JA; Mak A; Xiao Z; Roa W; Moore RB
J Urol; 2009 Mar; 181(3):1361-71. PubMed ID: 19157446
[TBL] [Abstract][Full Text] [Related]
23. Role of IG20 splice variants in TRAIL resistance.
Prabhakar BS; Mulherkar N; Prasad KV
Clin Cancer Res; 2008 Jan; 14(2):347-51. PubMed ID: 18223207
[TBL] [Abstract][Full Text] [Related]
24. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
[TBL] [Abstract][Full Text] [Related]
25. TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract.
Sadarangani A; Kato S; Espinoza N; Lange S; Llados C; Espinosa M; Villalón M; Lipkowitz S; Cuello M; Owen GI
Apoptosis; 2007 Jan; 12(1):73-85. PubMed ID: 17136491
[TBL] [Abstract][Full Text] [Related]
26. Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells.
Morello S; Sorrentino R; Porta A; Forte G; Popolo A; Petrella A; Pinto A
J Cell Physiol; 2009 Nov; 221(2):378-86. PubMed ID: 19562684
[TBL] [Abstract][Full Text] [Related]
27. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.
Iacomino G; Medici MC; Russo GL
Anticancer Res; 2008; 28(2A):855-64. PubMed ID: 18507029
[TBL] [Abstract][Full Text] [Related]
28. The clinical trail of TRAIL.
Duiker EW; Mom CH; de Jong S; Willemse PH; Gietema JA; van der Zee AG; de Vries EG
Eur J Cancer; 2006 Sep; 42(14):2233-40. PubMed ID: 16884904
[TBL] [Abstract][Full Text] [Related]
29. Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
Lee TJ; Um HJ; Min do S; Park JW; Choi KS; Kwon TK
Free Radic Biol Med; 2009 Jun; 46(12):1639-49. PubMed ID: 19345731
[TBL] [Abstract][Full Text] [Related]
30. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers.
Kendrick JE; Estes JM; Straughn JM; Alvarez RD; Buchsbaum DJ
Gynecol Oncol; 2007 Sep; 106(3):614-21. PubMed ID: 17602728
[TBL] [Abstract][Full Text] [Related]
31. The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next?
Bellail AC; Hao C
Expert Rev Anticancer Ther; 2012 May; 12(5):547-9. PubMed ID: 22594889
[No Abstract] [Full Text] [Related]
32. The NO TRAIL to YES TRAIL in cancer therapy (review).
Lee JY; Huerta-Yepez S; Vega M; Baritaki S; Spandidos DA; Bonavida B
Int J Oncol; 2007 Oct; 31(4):685-91. PubMed ID: 17786298
[TBL] [Abstract][Full Text] [Related]
33. Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells.
Taniguchi H; Yoshida T; Horinaka M; Yasuda T; Goda AE; Konishi M; Wakada M; Kataoka K; Yoshikawa T; Sakai T
Cancer Res; 2008 Nov; 68(21):8918-27. PubMed ID: 18974136
[TBL] [Abstract][Full Text] [Related]
34. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
35. Overcoming TRAIL resistance in ovarian carcinoma.
Bevis KS; Buchsbaum DJ; Straughn JM
Gynecol Oncol; 2010 Oct; 119(1):157-63. PubMed ID: 20638107
[TBL] [Abstract][Full Text] [Related]
36. Translating TRAIL-receptor targeting agents to the clinic.
den Hollander MW; Gietema JA; de Jong S; Walenkamp AM; Reyners AK; Oldenhuis CN; de Vries EG
Cancer Lett; 2013 May; 332(2):194-201. PubMed ID: 22531313
[TBL] [Abstract][Full Text] [Related]
37. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
[TBL] [Abstract][Full Text] [Related]
38. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
[TBL] [Abstract][Full Text] [Related]
39. Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells.
Beurel E; Blivet-Van Eggelpoël MJ; Kornprobst M; Moritz S; Delelo R; Paye F; Housset C; Desbois-Mouthon C
Biochem Pharmacol; 2009 Jan; 77(1):54-65. PubMed ID: 18938143
[TBL] [Abstract][Full Text] [Related]
40. The expression of TRAIL and its receptors in gastric cancer and the apoptotic effect of rh-TRAIL on SGC7901 cells.
Hu JK; Yang K; Li CM; Zhang B; Chen ZX; Chen XZ; Chen JP
Oncol Rep; 2009 Mar; 21(3):681-8. PubMed ID: 19212626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
